ATNM
Actinium Pharmaceuticals, Inc.
Biotechnology
Market Cap$38M
5Y Perf.-79.5%
Compare Stocks
4 / 10Try these comparisons:
Stock Comparison
ATNM vs PHAT vs ACAD vs RNAC
Revenue, margins, valuation, and 5-year total return — side by side.
PHAT
Phathom Pharmaceuticals, Inc.
Biotechnology
Market Cap$971M
5Y Perf.-73.5%
ACAD
ACADIA Pharmaceuticals Inc.
Biotechnology
Market Cap$3.86B
5Y Perf.-54.8%
RNAC
Cartesian Therapeutics, Inc.
Biotechnology
Market Cap$216M
5Y Perf.-92.1%
ATNM vs PHAT vs ACAD vs RNAC — Key Financials
Market cap, revenue, margins, and valuation side-by-side.
| Company Snapshot | ATNM | PHAT | ACAD | RNAC |
|---|---|---|---|---|
| Industry | Biotechnology | Biotechnology | Biotechnology | Biotechnology |
| Market Cap | $38M | $971M | $3.86B | $216M |
| Revenue (TTM) | $90K | $205M | $1.10B | $2M |
| Net Income (TTM) | $-35M | $-127M | $376M | $-152M |
| Gross Margin | -8.1% | 84.9% | 91.5% | -6.3% |
| Operating Margin | -414.9% | -47.1% | 7.4% | -51.4% |
| Forward P/E | — | — | 50.9x | — |
| Total Debt | $2M | $3M | $52M | $13M |
| Cash & Equiv. | $73M | $130M | $178M | $125M |
ATNM vs PHAT vs ACAD vs RNAC — Long-Term Stock Performance
Price return indexed to 100 at period start. Dividends excluded.
ATNM
PHAT
ACAD
RNAC
| Stock | May 20 | May 26 | Return |
|---|---|---|---|
| Actinium Pharmaceut… (ATNM) | 100 | 20.5 | -79.5% |
| Phathom Pharmaceuti… (PHAT) | 100 | 26.5 | -73.5% |
| ACADIA Pharmaceutic… (ACAD) | 100 | 45.2 | -54.8% |
| Cartesian Therapeut… (RNAC) | 100 | 7.9 | -92.1% |
Price return only. Dividends and distributions are not included.
Quick Verdict: ATNM vs PHAT vs ACAD vs RNAC
Each card shows where this stock fits in a portfolio — not just who wins on paper.
Bottom line: ACAD leads in 3 of 6 categories, making it the strongest pick for profitability and margin quality and capital preservation and lower volatility. Phathom Pharmaceuticals, Inc. is the stronger pick specifically for growth and revenue expansion and recent price momentum and sentiment. As sector peers, any of these can serve as alternatives in the same allocation.
ATNM
Actinium Pharmaceuticals, Inc.
The Defensive Pick
ATNM is the clearest fit if your priority is defensive.
- Beta 1.40, current ratio 9.14x
Best for: defensive
PHAT
Phathom Pharmaceuticals, Inc.
The Growth Leader
PHAT is the #2 pick in this set and the best alternative if growth and momentum is your priority.
- 216.9% revenue growth vs ATNM's -100.0%
- +409.6% vs RNAC's -19.6%
Best for: growth and momentum
ACAD
ACADIA Pharmaceuticals Inc.
The Income Pick
ACAD carries the broadest edge in this set and is the clearest fit for income & stability and growth exposure.
- beta 1.26
- Rev growth 11.9%, EPS growth 68.4%, 3Y rev CAGR 27.5%
- -22.9% 10Y total return vs PHAT's -50.3%
- Lower volatility, beta 1.26, Low D/E 4.3%, current ratio 3.83x
Best for: income & stability and growth exposure
RNAC
Cartesian Therapeutics, Inc.
The Secondary Option
RNAC lags the leaders in this set but could rank higher in a more targeted comparison.
Best for: healthcare exposure
See the full category breakdown
| Category | Winner | Why |
|---|---|---|
| Growth | PHAT | 216.9% revenue growth vs ATNM's -100.0% |
| Quality / Margins | ACAD | 34.3% margin vs ATNM's -384.4% |
| Stability / Safety | ACAD | Beta 1.26 vs RNAC's 2.03 |
| Dividends | Tie | None of these 4 stocks pay a meaningful dividend |
| Momentum (1Y) | PHAT | +409.6% vs RNAC's -19.6% |
| Efficiency (ROA) | ACAD | 26.2% ROA vs ATNM's -52.3% |
ATNM vs PHAT vs ACAD vs RNAC — Revenue Breakdown by Segment
How each company's revenue is distributed across its business units
FY 2023
Segment breakdown not available.
FY 2018
FY 2025
ATNM vs PHAT vs ACAD vs RNAC — Financial Metrics
Side-by-side numbers across 4 stocks — who leads on profitability, valuation, growth, and risk.
BEST OVERALLACADLAGGINGRNAC
Who Leads Where
ACAD leads in 4 of 6 categories
ATNM leads 0 • PHAT leads 0 • RNAC leads 0 • 1 tied
Explore the data ↓RNACCartesian Therapeutic…
0leads
PHATPhathom Pharmaceutica…
0leads
ATNMActinium Pharmaceutic…
0leads
ACADACADIA Pharmaceutical…
4leads
6 Total Categories
CATEGORYLEADERvs ATNMvs PHATMETRICS WON
Income & Cash FlowRevenue, margins, and cash flow strength
ACAD4/6
Valuation MetricsMultiples, price ratios, and targets
Tied
—
Profitability & EfficiencyROE, ROIC, leverage, and quality scores
ACAD5/7
Total Returns1Y, 3Y, 5Y total returns with dividends
ACAD4/6
Risk & VolatilityBeta, volatility, and downside exposure
ACAD2/2
Analyst OutlookRatings, price targets, and dividends
—
—
Income & Cash Flow (Last 12 Months)
ACAD leads this category, winning 4 of 6 comparable metrics.
Income & Cash Flow (Last 12 Months)
ACAD is the larger business by revenue, generating $1.1B annually — 12169.4x ATNM's $90,000. ACAD is the more profitable business, keeping 34.3% of every revenue dollar as net income compared to ATNM's -384.4%. On growth, PHAT holds the edge at +104.4% YoY revenue growth, suggesting stronger near-term business momentum.
| Metric | ATNMActinium Pharmace… | PHATPhathom Pharmaceu… | ACADACADIA Pharmaceut… | RNACCartesian Therape… |
|---|---|---|---|---|
| RevenueTrailing 12 months | $90,000 | $205M | $1.1B | $2M |
| EBITDAEarnings before interest/tax | -$37M | -$96M | $96M | -$90M |
| Net IncomeAfter-tax profit | -$35M | -$127M | $376M | -$152M |
| Free Cash FlowCash after capex | -$25M | -$97M | $212M | -$77M |
| Gross MarginGross profit ÷ Revenue | -8.1% | +84.9% | +91.5% | -6.3% |
| Operating MarginEBIT ÷ Revenue | -414.9% | -47.1% | +7.4% | -51.4% |
| Net MarginNet income ÷ Revenue | -384.4% | -62.0% | +34.3% | -85.5% |
| FCF MarginFCF ÷ Revenue | -278.2% | -47.5% | +19.4% | -43.6% |
| Rev. Growth (YoY)Latest quarter vs prior year | — | +104.4% | +9.7% | -92.9% |
| EPS Growth (YoY)Latest quarter vs prior year | +56.8% | +71.8% | -81.8% | -114.7% |
ACAD leads this category, winning 4 of 6 comparable metrics.
Valuation Metrics
Evenly matched — ATNM and PHAT and ACAD each lead in 1 of 3 comparable metrics.
Valuation Metrics
| Metric | ATNMActinium Pharmace… | PHATPhathom Pharmaceu… | ACADACADIA Pharmaceut… | RNACCartesian Therape… |
|---|---|---|---|---|
| Market CapShares × price | $38M | $971M | $3.9B | $216M |
| Enterprise ValueMkt cap + debt − cash | -$33M | $844M | $3.7B | $104M |
| Trailing P/EPrice ÷ TTM EPS | -0.96x | -4.04x | 9.85x | -1.63x |
| Forward P/EPrice ÷ next-FY EPS est. | — | — | 50.91x | — |
| PEG RatioP/E ÷ EPS growth rate | — | — | — | — |
| EV / EBITDAEnterprise value multiple | — | — | 26.91x | — |
| Price / SalesMarket cap ÷ Revenue | — | 5.55x | 3.61x | 77.34x |
| Price / BookPrice ÷ Book value/share | 1.12x | — | 3.15x | — |
| Price / FCFMarket cap ÷ FCF | — | — | 36.74x | — |
Evenly matched — ATNM and PHAT and ACAD each lead in 1 of 3 comparable metrics.
Profitability & Efficiency
ACAD leads this category, winning 5 of 7 comparable metrics.
Profitability & Efficiency
ACAD delivers a 35.6% return on equity — every $100 of shareholder capital generates $36 in annual profit, vs $-152 for ATNM. ACAD carries lower financial leverage with a 0.04x debt-to-equity ratio, signaling a more conservative balance sheet compared to ATNM's 0.05x. On the Piotroski fundamental quality scale (0–9), ACAD scores 6/9 vs RNAC's 1/9, reflecting solid financial health.
| Metric | ATNMActinium Pharmace… | PHATPhathom Pharmaceu… | ACADACADIA Pharmaceut… | RNACCartesian Therape… |
|---|---|---|---|---|
| ROE (TTM)Return on equity | -151.7% | — | +35.6% | — |
| ROA (TTM)Return on assets | -52.3% | -48.1% | +26.2% | -45.1% |
| ROICReturn on invested capital | — | — | +10.0% | — |
| ROCEReturn on capital employed | -59.5% | -76.2% | +10.1% | -25.0% |
| Piotroski ScoreFundamental quality 0–9 | 3 | 5 | 6 | 1 |
| Debt / EquityFinancial leverage | 0.05x | — | 0.04x | — |
| Net DebtTotal debt minus cash | -$71M | -$127M | -$126M | -$112M |
| Cash & Equiv.Liquid assets | $73M | $130M | $178M | $125M |
| Total DebtShort + long-term debt | $2M | $3M | $52M | $13M |
| Interest CoverageEBIT ÷ Interest expense | — | -2.37x | — | — |
ACAD leads this category, winning 5 of 7 comparable metrics.
Total Returns (Dividends Reinvested)
ACAD leads this category, winning 4 of 6 comparable metrics.
Total Returns (Dividends Reinvested)
A $10,000 investment in ACAD five years ago would be worth $10,710 today (with dividends reinvested), compared to $875 for RNAC. Over the past 12 months, PHAT leads with a +409.6% total return vs RNAC's -19.6%. The 3-year compound annual growth rate (CAGR) favors ACAD at 1.5% vs ATNM's -47.9% — a key indicator of consistent wealth creation.
| Metric | ATNMActinium Pharmace… | PHATPhathom Pharmaceu… | ACADACADIA Pharmaceut… | RNACCartesian Therape… |
|---|---|---|---|---|
| YTD ReturnYear-to-date | -10.9% | -22.2% | -13.7% | +20.7% |
| 1-Year ReturnPast 12 months | -12.9% | +409.6% | +52.4% | -19.6% |
| 3-Year ReturnCumulative with dividends | -85.9% | -0.9% | +4.7% | -77.1% |
| 5-Year ReturnCumulative with dividends | -83.3% | -65.0% | +7.1% | -91.3% |
| 10-Year ReturnCumulative with dividends | -97.7% | -50.3% | -22.9% | -98.1% |
| CAGR (3Y)Annualised 3-year return | -47.9% | -0.3% | +1.5% | -38.9% |
ACAD leads this category, winning 4 of 6 comparable metrics.
Risk & Volatility
ACAD leads this category, winning 2 of 2 comparable metrics.
Risk & Volatility
ACAD is the less volatile stock with a 1.26 beta — it tends to amplify market swings less than RNAC's 2.03 beta. A beta below 1.0 means the stock typically moves less than the S&P 500. ACAD currently trades 81.1% from its 52-week high vs RNAC's 52.4% drawdown — a narrower gap to the peak suggests stronger recent price momentum.
| Metric | ATNMActinium Pharmace… | PHATPhathom Pharmaceu… | ACADACADIA Pharmaceut… | RNACCartesian Therape… |
|---|---|---|---|---|
| Beta (5Y)Sensitivity to S&P 500 | 1.32x | 1.63x | 1.26x | 2.04x |
| 52-Week HighHighest price in past year | $1.95 | $18.31 | $27.81 | $15.57 |
| 52-Week LowLowest price in past year | $0.95 | $2.21 | $14.45 | $5.60 |
| % of 52W HighCurrent price vs 52-week peak | +62.6% | +66.8% | +81.1% | +52.4% |
| RSI (14)Momentum oscillator 0–100 | 52.8 | 56.0 | 44.2 | 68.7 |
| Avg Volume (50D)Average daily shares traded | 184K | 1.2M | 1.8M | 225K |
ACAD leads this category, winning 2 of 2 comparable metrics.
Analyst Outlook
Insufficient data to determine a leader in this category.
Analyst Outlook
Analyst consensus: PHAT as "Buy", ACAD as "Buy", RNAC as "Buy". Consensus price targets imply 101.7% upside for PHAT (target: $25) vs 54.1% for ACAD (target: $35).
| Metric | ATNMActinium Pharmace… | PHATPhathom Pharmaceu… | ACADACADIA Pharmaceut… | RNACCartesian Therape… |
|---|---|---|---|---|
| Analyst RatingConsensus buy/hold/sell | — | Buy | Buy | Buy |
| Price TargetConsensus 12-month target | — | $24.67 | $34.78 | $16.00 |
| # AnalystsCovering analysts | — | 9 | 37 | 10 |
| Dividend YieldAnnual dividend ÷ price | — | — | — | — |
| Dividend StreakConsecutive years of raises | 0 | — | — | — |
| Dividend / ShareAnnual DPS | — | — | — | — |
| Buyback YieldShare repurchases ÷ mkt cap | 0.0% | 0.0% | 0.0% | 0.0% |
Insufficient data to determine a leader in this category.
Key Takeaway
ACAD leads in 4 of 6 categories — strongest in Income & Cash Flow and Profitability & Efficiency. 1 category is tied.
Best OverallACADIA Pharmaceuticals Inc. (ACAD)Leads 4 of 6 categories
Loading custom metrics...
ATNM vs PHAT vs ACAD vs RNAC: Key Questions Answered
9 questions · data-driven answers · updated daily
01Is ATNM or PHAT or ACAD or RNAC a better buy right now?
For growth investors, Phathom Pharmaceuticals, Inc.
(PHAT) is the stronger pick with 216. 9% revenue growth year-over-year, versus -100. 0% for Actinium Pharmaceuticals, Inc. (ATNM). ACADIA Pharmaceuticals Inc. (ACAD) offers the better valuation at 9. 9x trailing P/E (50. 9x forward), making it the more compelling value choice. Analysts rate Phathom Pharmaceuticals, Inc. (PHAT) a "Buy" — based on 9 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.
02Which is the better long-term investment — ATNM or PHAT or ACAD or RNAC?
Over the past 5 years, ACADIA Pharmaceuticals Inc.
(ACAD) delivered a total return of +7. 1%, compared to -91. 3% for Cartesian Therapeutics, Inc. (RNAC). Over 10 years, the gap is even starker: ACAD returned -22. 9% versus RNAC's -97. 9%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.
03Which is safer — ATNM or PHAT or ACAD or RNAC?
By beta (market sensitivity over 5 years), ACADIA Pharmaceuticals Inc.
(ACAD) is the lower-risk stock at 1. 26β versus Cartesian Therapeutics, Inc. 's 2. 04β — meaning RNAC is approximately 62% more volatile than ACAD relative to the S&P 500. On balance sheet safety, ACADIA Pharmaceuticals Inc. (ACAD) carries a lower debt/equity ratio of 4% versus 5% for Actinium Pharmaceuticals, Inc. — giving it more financial flexibility in a downturn.
04Which is growing faster — ATNM or PHAT or ACAD or RNAC?
By revenue growth (latest reported year), Phathom Pharmaceuticals, Inc.
(PHAT) is pulling ahead at 216. 9% versus -100. 0% for Actinium Pharmaceuticals, Inc. (ATNM). On earnings-per-share growth, the picture is similar: ACADIA Pharmaceuticals Inc. grew EPS 68. 4% year-over-year, compared to -52. 6% for Cartesian Therapeutics, Inc.. Over a 3-year CAGR, ACAD leads at 27. 5% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.
05Which has better profit margins — ATNM or PHAT or ACAD or RNAC?
ACADIA Pharmaceuticals Inc.
(ACAD) is the more profitable company, earning 36. 5% net margin versus -384. 4% for Actinium Pharmaceuticals, Inc. — meaning it keeps 36. 5% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: ACAD leads at 9. 8% versus -414. 9% for ATNM. At the gross margin level — before operating expenses — RNAC leads at 100. 0%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.
06Is ATNM or PHAT or ACAD or RNAC more undervalued right now?
Analyst consensus price targets imply the most upside for PHAT: 101.
7% to $24. 67.
07Which pays a better dividend — ATNM or PHAT or ACAD or RNAC?
None of the stocks in this comparison currently pay a material dividend.
All are effectively zero-yield and should be held for capital appreciation rather than income.
08Is ATNM or PHAT or ACAD or RNAC better for a retirement portfolio?
For long-horizon retirement investors, ACADIA Pharmaceuticals Inc.
(ACAD) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 1. 26)). Cartesian Therapeutics, Inc. (RNAC) carries a higher beta of 2. 04 — meaning larger drawdowns in market downturns, which matters significantly when you cannot wait years for a recovery. Both have compounded well over 10 years (ACAD: -22. 9%, RNAC: -97. 9%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.
09What are the main differences between ATNM and PHAT and ACAD and RNAC?
Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both.
In terms of investment character: ATNM is a small-cap quality compounder stock; PHAT is a small-cap high-growth stock; ACAD is a small-cap deep-value stock; RNAC is a small-cap quality compounder stock. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.
Find Stocks Like These
Explore pre-built screens for each stock's profile, or build a custom screen to find stocks that outperform all of them.
Revenue Growth>
%
(ATNM: -100.0% · PHAT: 104.4%)You Might Also Compare
Based on how these companies actually compete and overlap — not just which sector they're filed under.